Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirexatamab - Leap Therapeutics

Next Previous
Drug Profile

Sirexatamab - Leap Therapeutics

Alternative Names: DKN-01; LY-2812176

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer BeOne Medicines; Leap Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Ovarian cancer
  • Phase I/II Prostate cancer
  • No development reported Multiple myeloma; Non-small cell lung cancer; Sarcoma; Solid tumours; Squamous cell cancer; Uterine cancer

Most Recent Events

  • 12 Nov 2025 Leap Therapeutics anticipates approval for Sirexatamab for Colorectal cancer in Europe and USA
  • 12 Nov 2025 Updated efficacy data from the phase II DeFianCe trial in Colorectal cancer released by Leap Therapeutics
  • 17 Oct 2025 Efficacy and adverse events data from the phase II DeFianCe trial in Colorectal cancer released presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top